以下は、Lリジンとヘアロスに関する特許取得番号とその詳細
L-LYSINE AND THE TREATMENT OF HAIR LOSS
US Patent 6136860
Applicant: Bio-Scientific Ltd., London, UK
"Studies involving the administration according to the present invention
of L-lysine to those suffering from increased hair shedding show a remarkable
increase in scalp hair growth."
"Typically, the L-lysine is administered in a daily dose of from 200
to 2000 mg, and more usually in a daily dose of 500 to 1500 mg, e.g. in
the form of a 500 mg dose administered orally once, twice or three times
a day. L-lysine may conveniently be administered orally, for example as
tablets, capsules."
"We have also discovered that administration of lysine to patients
results in a dramatic increase in the efficacy of known treatments for
genetic hair loss (which term covers a number of conditions variously referred
to as androgen-dependent alopecia, androgenic alopecia, androgenetic alopecia,
common baldness, female baldness, diffuse hair loss and male pattern baldness)."
"Thus, in a further aspect of the present invention there is provided
a kit including a plurality of separate containers, each containing at
least one active agent useful in a combination therapy for the treatment
of genetic hair loss, wherein said kit includes L-lysine and at least one
further active agent selected from minoxidil, anti-androgens, 5.alpha.-reductase
inhibitors, aromatase inhibitors."
"The co-administration of L-lysine with known treatments for genetic
hair loss such as minoxidil and anti-androgens results in a significant
improvement in the efficacy of the treatment."
Treatment of Women Suffering from Genetic Hair Loss.
"The effect of the administration of lysine on the efficacy of known
treatments for genetic hair loss was investigated as follows."
"Women suffering from genetic hair loss, all of whom had adequate
iron stores within the normal range at the start of the test (i.e. serum
ferritin levels of greater than 40 mg/ml) were divided into four groups"
"The first group (17 women) was treated with minoxidil only (in the
form of a topical formulation comprising 3% minoxidil by weight)."
"The second group (15 women) had a combined treatment of minoxidil
(again as a topical formulation comprising 3% minoxidil by weight) and
an oral anti-androgen chosen from cyproterone acetate, medroxyprogesterone
and spironolactone. The first two anti-androgens were administered in combination
with ethinylestradiol or an oral contraceptive. The particular anti-androgen
administered was chosen on the basis of clinical need."
"The third group (8 women) received a combined treatment of minoxidil
(again as a topical formulation comprising 3% minoxidil by weight) and
500 to 1500 mg per day of L-lysine (administered orally)."
"The fourth group (13 women) received a combined treatment comprising
minoxidil (again as a topical formulation comprising 3% minoxidil by weight),
an oral anti-androgen (administeredas to the second group above) and 500
to 1500 mg per day of L-lysine (administered orally)."
"The results in Table 5 suggest that the co-administration of L-lysine
to patients being treated for genetic hair loss with known treatments such
as the topical administration of minoxidil and/or the oral administration
of anti-androgens results in a considerable improvement in the efficacy
of these known treatments."
|
